Clinical trials: Brachytherapy
Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device (DaRT) as a treatment prior to additional radiation or chemo therapy.
- Trial name
- NCT05065346
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT
- Where
- Israel
- Volunteers
- 79 people
- Sponsor
- Alpha Tau Medical LTD.
Liver Metastases
Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases
This is a single center study enrolling up to 10 patients. The primary objective is to Evaluate the feasibility and safety of the DaRT for the treatment of Liver Metastases.
- Trial name
- NCT05829291
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Lung Cancer, Lung Cancer Stage I
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing…
- Conditions
- Lung Cancer, Lung Cancer Stage I, Lung Cancer Stage II
- Trial name
- NCT03290534
- Testing
- CivaSheet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CivaTech Oncology
Pancreatic Cancer
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
This is the first study investigating the safety of 32P BioSilicon in patients with advanced,unresectable pancreatic cancer who are also receiving standard intravenous gemcitabine chemotherapy.
- Trial name
- NCT00346281
- Testing
- 32P BioSilicon
- Where
- 2 sites in Singapore, United Kingdom
- Volunteers
- 15 people
- Sponsor
- pSiMedica Limited
Cervical Cancer
Post Market Clinical Follow-up Study Venezia
The investigational device is the Advanced Gynecological Applicator (AGA) Venezia configuration, an applicator to treat locally advanced stage cervical cancer.
- Trial name
- NCT03958357
- Testing
- Advanced Gynecological Applicator configuration
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 41 people
- Sponsor
- Nucletron Operations BV
Pancreatic Cancer
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
- Trial name
- NCT02843945
- Testing
- Directional Brachytherapy Source Implant
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- CivaTech Oncology
Breast Cancer
Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer
This is a physician sponsored multi-center, non-randomized, prospectively enrolling data collection study of patients with early stage breast cancer treated with electronic brachytherapy at the time of surgical resection of the…
- Trial name
- NCT02040493
- Testing
- Intra-operative radiation therapy (IORT)
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Xoft, Inc.
Malignant Tumor
Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors
This study is a Compassionate clinical study for the treatment of Malignant Tumors. The primary endpoint of the study is to assess the frequency, severity and causality of acute adverse events related to the DaRT treatment.
- Trial name
- NCT05781555
- Testing
- Experimental: DaRT seeds
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Alpha Tau Medical LTD.
Unresectable Locally Advanced Pancreatic Carcinoma
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy FDA regulatory requirements.
- Trial name
- OncoPaC-1 (NCT03076216)
- Testing
- OncoSil™
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- OncoSil Medical Limited
Endometrial Cancer
Signatera Assessment in Early-Stage Endometrial Cancer
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer.
- Trial name
- SIGNAL-EMC 101 (NCT07339384)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Where
- 12 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- Natera, Inc.
Unresectable Hepatocellular Carcinoma
Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
The goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.
- Trial name
- NCT06310590
- Testing
- NRT6003 Injection
- Where
- 10 sites in China
- Volunteers
- 40 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
Carcinoma, Hepatocellular, Hepatoma
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC).
- Trial name
- NCT00503867
- Testing
- SIR-Spheres microspheres
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sirtex Medical
Breast Cancer, Carcinoma
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
PRINCIPAL INVESTIGATORS Rakesh Patel, MD- Radiation Oncologist Peter Beitsch, MD- Breast Surgeon REGISTRY DESIGN Multicenter, non-randomized, post market registry of intracavitary accelerated partial breast irradiation in…
- Conditions
- Breast Cancer, Carcinoma, Lumpectomy, Ductal Carcinoma in Situ
- Trial name
- EXIBT (NCT00742222)
- Testing
- Electronic Brachytherapy, Intracavitary accelerated partial breast irradiation
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- Xoft, Inc.
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Uveal Melanoma
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
- Trial name
- NCT07015190
- Testing
- Darovasertib, Primary Local Therapy
- Where
- 94 sites in United States, Australia and 19 more
- Volunteers
- 520 people
- Sponsor
- IDEAYA Biosciences
Squamous Cell Carcinoma, Alpha Radiation
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral…
- Conditions
- Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous
- Trial name
- DaRT (NCT06615635)
- Testing
- DaRT seeds
- Where
- 11 sites in United States, Israel
- Volunteers
- 28 people
- Sponsor
- Alpha Tau Medical LTD.
Healthy Subjects (HS)
A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.
This is a phase 1, single-centre, single-group, nonrandomized, noncomparative, open-label, single-dose study to evaluate the safety, biodistribution, internal radiation dosimetry, and effective dose of DaTSCAN™ ioflupane (123I)…
- Trial name
- NCT04564092
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03737734
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.
Glioblastoma, Recurrent Glioblastoma
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
The purpose of this trial is to assess the overall survival of patients treated with the Xoft Axxent eBx System and post-radiation adjuvant Bevacizumab for single-fraction IORT following maximal neurosurgical resection of…
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM, Recurrent GBM
- Trial name
- IORT (NCT04681677)
- Testing
- Radiation: Intra-operative Radiation Therapy - IORT, Bevacizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Xoft, Inc.